|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,935.50 INR | -0.17% |
|
+1.61% | +12.55% |
| 07-10 | India's Dr Reddy's posts worst week in 3 years as semaglutide setback stokes growth fears | RE |
| 06-25 | Jefferies quarterly profit misses estimates as asset management weighs | RE |
| Market Cap | 4,644B 48.69B 42.59B 39.28B 36.28B 68.85B 70B 469B 184B 2,288B 183B 179B 7,865B | P/E 2027 * |
35.3x | P/E 2028 * | 29.9x |
|---|---|---|---|---|---|
| Enterprise Value | 4,371B 45.83B 40.08B 36.97B 34.15B 64.8B 65.89B 442B 173B 2,153B 172B 168B 7,402B | EV / Sales 2027 * |
6.68x | EV / Sales 2028 * | 5.9x |
| Free-Float |
44.39% | Yield 2027 * |
0.82% | Yield 2028 * | 0.92% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.17% | ||
| 1 week | +1.61% | ||
| Current month | +3.92% | ||
| 1 month | +8.35% | ||
| 3 months | +16.96% | ||
| 6 months | +11.89% | ||
| Current year | +12.55% |
| 1 week | 1,875.1 |  | 1,953.9 |
| 1 month | 1,792.5 | | 1,953.9 |
| Current year | 1,583.7 | | 1,953.9 |
| 1 year | 1,548 | | 1,953.9 |
| 3 years | 1,063.85 | | 1,960.35 |
| 5 years | 666.4 | | 1,960.35 |
| 10 years | 312 | | 1,960.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.17% | +1.61% | +16.42% | +85.22% | 48.69B | |
| +1.04% | -1.02% | +69.47% | +115.88% | 36.38B | |
| -0.13% | -1.29% | -2.60% | +41.58% | 12.19B | |
| -0.71% | +0.89% | +18.28% | +97.87% | 12.04B | |
| -0.76% | +0.38% | +33.16% | +123.08% | 9.04B | |
| -0.86% | +0.37% | +52.61% | -3.54% | 7.06B | |
| +0.75% | -0.82% | +17.49% | +44.79% | 7.09B | |
| +0.69% | +3.25% | +19.90% | +243.91% | 6.75B | |
| +5.45% | -7.36% | -17.93% | +13.17% | 6.1B | |
| +1.24% | +0.67% | +29.22% | +138.06% | 4.38B | |
| Average | +0.65% | -0.31% | +23.60% | +90.00% | 14.97B | |
| Weighted average by Cap. | +0.37% | +0.11% | +29.81% | +92.08% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 654B 6.86B 6B 5.53B 5.11B 9.7B 9.86B 66.11B 25.96B 322B 25.75B 25.19B 1,108B | 729B 7.65B 6.69B 6.17B 5.7B 10.81B 10.99B 73.72B 28.95B 359B 28.71B 28.09B 1,235B |
| Net income | 133B 1.39B 1.22B 1.12B 1.04B 1.97B 2B 13.4B 5.26B 65.32B 5.22B 5.11B 225B | 157B 1.64B 1.44B 1.32B 1.22B 2.32B 2.36B 15.82B 6.21B 77.13B 6.16B 6.03B 265B |
| Net Debt | -273B -2.86B -2.51B -2.31B -2.13B -4.05B -4.12B -27.62B -10.84B -135B -10.76B -10.52B -463B | -341B -3.58B -3.13B -2.89B -2.67B -5.06B -5.15B -34.51B -13.55B -168B -13.44B -13.15B -578B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/07/26 | ₹1,935.50 | -0.17% | 1,478,172 |
| 09/07/26 | ₹1,938.70 | +2.67% | 4,446,201 |
| 08/07/26 | ₹1,888.20 | -0.80% | 2,785,926 |
| 07/07/26 | ₹1,903.40 | -0.49% | 2,060,613 |
| 06/07/26 | ₹1,912.80 | +0.42% | 1,213,635 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
